Paige White, MD
Urology · Gulfport, MSNPI 1194825216
Payments from drug & device makers
What this record shows
Axonics, Inc. accounts for 67.5% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $2,526 and has fallen 86.4% since, to $343 in 2025.
Across 142 payments — averaging $48.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$5K
- Coloplast$496
- Sumitomo Pharma America, Inc.$494
- Astellas Pharma US Inc$223
- Urovant Sciences Inc$196
- Medtronic$196
- plus $632 from 11 others
What the payments were for
- Travel & lodging$3,26647%
- Food & beverage$3,61153%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 40 | $4,640 |
| Coloplast | 10 | $496 |
| Sumitomo Pharma America, Inc. | 42 | $494 |
| Astellas Pharma US Inc | 10 | $223 |
| Urovant Sciences Inc | 6 | $196 |
| Medtronic(2 entities) | 8 | $196 |
| AbbVie(2 entities) | 10 | $166 |
| Boston Scientific | 3 | $131 |
| Siemens Medical Solutions USA, Inc. | 1 | $92 |
| Olympus America Inc. | 5 | $69 |
| Urogen Pharma, Inc. | 1 | $46 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $44 |
| Kerecis Limited | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $21 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Teleflex LLC | 1 | $13 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,877 in reported general payments places this provider in the 80th percentile of 94 urology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 292 | $245,543 |
| GemtesaVibegron | 122 | $110,755 |
| ElmironPentosan Polysulfate Sodium | 12 | $11,269 |
| Methenamine Hippurate | 82 | $7,366 |
| Mirabegron ErMirabegron | 15 | $6,730 |
| Estradiol | 82 | $5,651 |
| Oxybutynin Chloride ErOxybutynin Chloride | 197 | $4,753 |
| Tolterodine Tartrate ErTolterodine Tartrate | 33 | $3,969 |
| Tamsulosin Hcl | 177 | $1,946 |
| Solifenacin Succinate | 18 | $1,689 |
| Potassium Citrate ErPotassium Citrate | 19 | $1,501 |
| Desmopressin Acetate | 22 | $1,030 |
| Finasteride | 63 | $993 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 52 | $866 |
| CefuroximeCefuroxime Axetil | 32 | $641 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $223 | $245,543292 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $494 | $110,755122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 94 urology providers in Mississippi.
Other urology in Gulfport
- William HughesGulfport$8K
- Joseph CottoneGulfport$6K
- Jacob JornsGulfport$4K
- Sean DouglasHattiesburg$40K
- Robert HollabaughSouthaven$17K
- Kristopher WhiteheadTupelo$17K
- Harold BlalockJackson$15K
- Jon PoseyTupelo$13K
- Paul FarabaughTupelo$13K
- Clarance FarmerTupelo$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.